Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2A | Q9UIF9 | 6/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 4/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13422226 | 0.78 | HPGDS (0.52) | BAZ2AHPGDSPLATAOC3MEN1 | |
| SCHEMBL12620707 | 0.71 | HPGDS (0.42) | BAZ2AHPGDSPLATMEN1KMT2A | |
| SCHEMBL1042507 | 0.70 | HPGDS (0.47) | BAZ2AHPGDSAOC3CHRM4MEN1 | |
| SCHEMBL7258954 | 0.70 | HPGDS (0.49) | BAZ2AHPGDSAOC3 | |
| SCHEMBL18997369 | 0.70 | ALDH1A1 (0.43) | BAZ2AHPGDSMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL17541611 | 0.69 | HPGDS (0.46) | BAZ2AHPGDSAOC3CHRM4MEN1 | |
| SCHEMBL20195251 | 0.69 | HPGDS (0.52) | BAZ2AHPGDSAOC3MEN1KMT2A | |
| SCHEMBL4262100 | 0.68 | HPGDS (0.59) | BAZ2AHPGDSPLATMEN1KMT2A | |
| Bromide SCHEMBL2983628 | 0.67 | HPGDS (0.57) | BAZ2AHPGDSPLATMEN1KMT2A | |
| SCHEMBL3765828 | 0.66 | HPGDS (0.56) | BAZ2AHPGDSPLATAOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436186-B2 | Thiazolyl piperidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110105505-A1 | THIAZOLYL PIPERIDINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105505-A1 | THIAZOLYL PIPERIDINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105505-A1 | THIAZOLYL PIPERIDINE DERIVATIVES | SPHK1, S1PR1, SPHK2 | BAZ2A 1741/4885HPGDS 1318/4885PLAT 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.